RecruitingNCT05432739

Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Sponsor

Royal Marsden NHS Foundation Trust

Enrollment

500 participants

Start Date

Apr 7, 2021

Study Type

OBSERVATIONAL

Conditions

Lung Cancer

Summary

NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whether artificial intelligence and machine learning based radiomics approaches can be used to distinguish between benign disease and malignancy in a new lung nodule after a previously treated cancer, and where malignant to differentiate between metastatic recurrence or a new primary lung cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a blood-based immune test can help predict whether a small lung nodule (a spot found on a chest scan) is cancerous or harmless. The goal is to develop a non-invasive way to avoid unnecessary biopsies or surgeries. **You may be eligible if:** - You are over 18 years old - You have a lung nodule being monitored or investigated by your doctor **You may NOT be eligible if:** - You have had a cancer diagnosis in the last 5 years - You have an active infection (including tuberculosis or a fungal infection) - You have had a recent COVID-19 infection (within the last 4 weeks) - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.